Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses. It has a research collaboration with Keck School of Medicine of University of Southern California using pelareorep in combination with Keytruda, Velcade, and dexamethasone to treat multiple myeloma; and a clinical collaboration with SOLTI breast cancer research. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+1-403-6707380
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date11/11/2019 (Estimated)
OptionableNot Optionable
Oncolytics Biotech (TSE:ONC) Frequently Asked Questions
What is Oncolytics Biotech's stock symbol?
Oncolytics Biotech trades on the Toronto Stock Exchange (TSX) under the ticker symbol "ONC."
How were Oncolytics Biotech's earnings last quarter?
Oncolytics Biotech, Inc. (TSE:ONC) posted its quarterly earnings results on Tuesday, August, 13th. The company reported ($0.26) earnings per share (EPS) for the quarter. View Oncolytics Biotech's Earnings History.
When is Oncolytics Biotech's next earnings date?
What price target have analysts set for ONC?
2 equities research analysts have issued 1 year target prices for Oncolytics Biotech's shares. Their predictions range from C$9.00 to C$9.00. On average, they anticipate Oncolytics Biotech's share price to reach C$9.00 in the next twelve months. This suggests a possible upside of 847.4% from the stock's current price. View Analyst Price Targets for Oncolytics Biotech.
What is the consensus analysts' recommendation for Oncolytics Biotech?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oncolytics Biotech in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Oncolytics Biotech.
Has Oncolytics Biotech been receiving favorable news coverage?
News headlines about ONC stock have been trending somewhat negative recently, according to InfoTrie. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Oncolytics Biotech earned a media sentiment score of -1.3 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Oncolytics Biotech.
Who are some of Oncolytics Biotech's key competitors?
Some companies that are related to Oncolytics Biotech include Oxford Biodynamics (OBD), Immutep (IMM), Helix Biopharma (HBP), Imugene (IMU), Tiziana Life Sciences (TILS), Ampio Pharmaceuticals (AMPE), Orgenesis (ORGS), Circassia Pharmaceuticals (CIR), Equillium (EQ), Pediapharm (PDP), Medicure (MPH), ReNeuron Group (RENE), Promis Neurosciences (PMN), AquaBounty Technologies (AQB) and Mereo BioPharma Group (MPH).
What other stocks do shareholders of Oncolytics Biotech own?
Who are Oncolytics Biotech's key executives?
Oncolytics Biotech's management team includes the folowing people:
- Dr. Matthew C. Coffey, Pres, CEO & Director
- Mr. Kirk J. Look, Chief Financial Officer
- Mr. Andrew R. de Guttadauro, Global Head of Bus. Devel. & Pres of Oncolytics Biotech (U.S.) Inc (Age 52)
- Mr. Michael Moore, VP of Investor Relations & Corp. Communications
- Dr. Rita Laeufle, Chief Medical Officer
How do I buy shares of Oncolytics Biotech?
Shares of ONC and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Oncolytics Biotech's stock price today?
One share of ONC stock can currently be purchased for approximately C$0.95.
How big of a company is Oncolytics Biotech?
What is Oncolytics Biotech's official website?
How can I contact Oncolytics Biotech?
Oncolytics Biotech's mailing address is 1167 Kensington Cres Nw Suite 210 Calgary Alberta Canada T2n 1X7, CALGARY, AB 00000, Canada. The company can be reached via phone at +1-403-6707380.
MarketBeat Community Rating for Oncolytics Biotech (TSE ONC)
MarketBeat's community ratings are surveys of what our community members think about Oncolytics Biotech and other stocks. Vote "Outperform" if you believe ONC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONC will underperform the S&P 500 over the long term. You may vote once every thirty days.
